Research on lung adenocarcinoma, the most common type of non-small cell lung cancer

From November 2025

Ultrasensitive ctDNA detection is highly prognostic in NSCLC, improving disease stratification (ref: Black doi.org/10.1016/j.cell.2025.10.020/)
MUC1-C is essential for TKI resistance in NSCLC, presenting a target for antibody-drug conjugates (ref: Takamori doi.org/10.1038/s41392-025-02482-7/)
CD8+CX3CR1+ T cells are enriched in NSCLC tumors treated with neoadjuvant immune checkpoint blockade (ref: Dai doi.org/10.1038/s41416-025-03160-9/)
Lorlatinib shows durable efficacy in TKI-naive advanced ROS1-positive NSCLC (ref: Ahn doi.org/10.1001/jamaoncol.2025.5097/)
EFS2 and PFS2 may serve as more accurate measures of durable benefit in immunotherapy trials (ref: Jimenez-Labaig doi.org/10.1136/jitc-2025-013072/)
MZT2B upregulation correlates with poor prognosis in NSCLC, highlighting its potential as a therapeutic target (ref: Ding doi.org/10.1038/s41419-025-08182-y/)
IL-6 inhibition restores chemosensitivity in NSCLC, suggesting a promising therapeutic strategy (ref: Dai doi.org/10.5306/wjco.v16.i10.112097/)
The integration of ucfDNA as a biomarker offers a noninvasive approach for cancer detection in NSCLC (ref: Yajima doi.org/10.1016/j.ctrv.2025.103047/)

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec